AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced n...

Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies

AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously announced $50 bill...

AstraZeneca to invest $2 billion as part of US manufacturing push

Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don't work equally well in pat...

Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes

London's export-focused FTSE 100 rose to a new intraday record peak on Tuesday, buoyed by a weakening pound after economic data revealed rising une...

FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines

Shares in AstraZeneca rose past their September 2024 peak on Tuesday, hitting a fresh record high and cementing the company's position as the large...

AstraZeneca hits record high, cements lead as UK's biggest stock

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to $15.19 billion from $13.57...

AstraZeneca Revenue Climbs on Pipeline Strength, U.S. Price Deal

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of key cancer, heart and kidney disease drugs, prompting L...

AstraZeneca beats third-quarter revenue and profit expectations

AstraZeneca breached the UK pharmaceutical industry's code of practice by using a claim that misleadingly implied its Symbicort asthma drug was sui...

AstraZeneca found in breach of industry code over Symbicort marketing, industry body says

An executive at AstraZeneca says breast-cancer drugs that the company highlighted at an industry conference over the weekend could represent $10 bi...

AstraZeneca hails major breakthroughs with breast-cancer drugs

AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a pote...

AstraZeneca's Datroway extends survival in aggressive breast cancer

AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer...

AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment

AstraZeneca CEO Pascal Soriot looked relaxed standing in the Oval Office on Friday as U.S. President Donald Trump unveiled a medicine deal that wil...

Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump

AstraZeneca PLC looks poised to announce a deal with U.S. President Donald Trump that's focused on lowering drug prices, in a move that would see t...

AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.

The agreement follows last week's deal with Pfizer.